Jessica Tucci
About Jessica Tucci
Jessica Tucci is a Principal Scientist with expertise in flow cytometry and a focus on analytical method validation in autologous cell therapies. She holds a Bachelor's Degree in Experimental Psychology from Clemson University and a Master's Degree in Biotechnology from Temple University, and is currently pursuing an MBA at Temple University.
Work at Adaptimmune
Jessica Tucci has held multiple positions at Adaptimmune, starting as a QC Specialist from 2017 to 2020. In this role, she focused on quality control processes within the organization. She then advanced to the position of Senior Scientist from 2020 to 2021, where she contributed to scientific research and development. Since 2021, she has been serving as a Principal Scientist, where she continues to leverage her expertise in analytical methods and process analytics to support the company's mission in cancer therapies.
Education and Expertise
Jessica Tucci earned her Bachelor’s Degree in Experimental Psychology from Clemson University, studying from 2005 to 2008. She later obtained a Master’s Degree in Biotechnology from Temple University, completing her studies in 2016. Currently, she is pursuing a Master of Business Administration (MBA) at Temple University, which she began in 2021. Her expertise includes flow cytometry, product characterization, and analytical method validation, particularly in the context of autologous cell therapies.
Background
Before joining Adaptimmune, Jessica Tucci worked at Glaxo Smith Kline Pharmaceuticals in various roles. She served as a Scientific Student Worker from 2015 to 2016 and again in 2016, where she gained foundational experience in the pharmaceutical industry. Additionally, she worked as a Bench Scientist under a contract with ZeroChaos from 2016 to 2017. She also contributed to research at Bangasser Lab at Temple University in 2015.
Achievements
Jessica Tucci is passionate about enhancing in-process analytics to improve the reliability and ease of analytical assays. She advocates for better analytics that can positively impact cancer patient outcomes. Her work emphasizes the importance of understanding process impacts on products, aiming to streamline the transition from research use only (RUO) to good manufacturing practice (GMP) environments.